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Abstract
Patients often see primary care physicians with symptoms that might signal colorectal cancer but
are also common in adults without cancer. Physicians and patients must then make a difficult
decision about whether and how aggressively to evaluate the symptom. Favoring referral is that
missed diagnoses lead to unnecessary testing, prolonged uncertainty, and continuing symptoms;
also, the physician will suffer chagrin. It is not clear that diagnostic delay leads to progression to a
more advanced stage. Against referral is that proper evaluation includes colonoscopy, with
attendant inconvenience, discomfort, cost, and risk. The article by Hamilton et al, published this
month in BMC Medicine, provides strong estimates of the predictive value of the various symptoms
and signs of colorectal cancer and show how much higher predictive values are with increasing age
and male sex. Unfortunately, their results also make clear that most colorectal cancers present
with symptoms with low predictive values, < 1.2%. Models that include a set of predictive variables,
that is, risk factors, age, sex, screening history, and symptoms, have been developed to guide
primary prevention and clinical decision-making and are more powerful than individual symptoms
and signs alone. Although screening for colorectal cancer is increasing in many countries, cancers
will still be found outside screening programs so primary care physicians will remain at the front
line in the difficult task of distinguishing everyday symptoms from life-threatening cancer.
Commentary
Patients often see primary care physicians for symptoms
that might signal colorectal cancer, raising difficult ques-
tions. Which patients should be evaluated? How aggres-
sively should they be worked up? If another cause for the
symptom is found, such as hemorrhoids for rectal bleed-
ing, should that set the matter to rest or should a cancer
diagnosis still be pursued?
Table 1 lists 15 symptoms of colorectal cancer that have
been suggested in textbooks and supported by research
evidence [1]. Unfortunately, many of these same symp-
toms, especially constipation and fatigue, are common in
patients who do not have colorectal cancer. True, some
clinical presentations, such as bowel obstruction or severe
abdominal or rectal pain, are sufficiently unusual and dra-
matic events that they would prompt quick evaluation in
any case. However, most symptoms of colorectal cancer
are not so compelling. As a result, first-contact physicians
are in the familiar position of looking for a needle in a
haystack.
The stakes are high on either side of the decision. If the
diagnosis is missed the patient will undergo unnecessary
testing, prolonged uncertainty, and continuing symptoms
until the diagnosis is finally made. The clinician will suffer
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chagrin [2] and in some settings he or she might also
worry about malpractice claims. On the other hand,
proper evaluation, which involves complete visualization
of the large bowel by colonoscopy, is a big undertaking,
with the inconvenience of a day off work, the discomfort
of bowel cleansing if not the procedure itself, financial
costs to the patients or society, and a small risk of perfora-
tion, bleeding, or other complications [3].
Does diagnostic delay allow colorectal cancer to progress
from a local to advanced stage, diminishing the possibility
of cure? One might think so but the evidence is mixed and
for the most part against this possibility [1,4-6]. The rela-
tionship between diagnostic delay and cancer stage or sur-
vival is at the very least complex. For example, a study of
777 consecutive colorectal cancer patients found that
shorter duration of symptoms was associated with
advanced tumor stage [4]. This makes sense because esti-
mates of the transition time from localized to advanced
colorectal cancers is measured in years, much longer than
the time from symptoms to diagnosis in most patients.
Also, advanced cancers causing bowel obstruction would
be evaluated promptly while some slow-growing, local-
ized tumors may not declare themselves (perhaps with
systemic symptoms such as fatigue or weight loss) for
many months. Therefore, while the other consequences of
diagnostic delay are certainly in play, progression to more
advanced stage may not be.
The article by Hamilton et al, published this month in
BMC Medicine, advances the evidence base for early diag-
nosis of colorectal cancer [7]. The investigators were fortu-
nate to have access to a large database of patients in
general practices in the UK, with data on 23 candidate
symptoms and signs of colorectal cancer (or surrogates for
some of them, such as drugs prescribed for constipation).
The authors calculated likelihood ratios for symptoms
and signs from data on 5477 cases of colorectal cancer and
controls matched for age, sex, and site. They then esti-
mated the positive predictive values of these symptoms
and signs by applying their likelihood ratios to national
data on the incidence of colorectal cancer, using Bayes'
theorem: prior odds × likelihood ratio = posterior odds
(where the national incidence data was used to derive
prior odds). This approach is sound if one is willing to
assume that patients in the general practices and in the
nation as a whole are comparable. Given the size of the
database, the authors could describe the predictive value
of each symptom and sign with clinically useful precision,
even though colorectal cancer is uncommon. The authors
analyzed the data and described their results with an
admirable grasp of both the scientific issues and the clini-
cal realities of colorectal cancer presentation in general
practice.
The Hamilton study identified predictive variables that
have long been part of clinical lore and more recently con-
firmed by clinical research. With their large sample size,
the authors were able to go further to show how power-
fully age, and to a lesser extent sex, affect predictive values
for this condition. However, the authors admit that their
study could not solve the problem of early diagnosis,
mainly because most patients presented with symptoms
with low predictive values. The presenting symptoms for
73% of colorectal cancer patients had predictive values of
< 1.2%. Although two symptoms (rectal bleeding and
change in bowel habits) had relatively high positive pre-
dictive values, they were uncommon. Therefore, physi-
cians must still wrestle with referral decisions for the
larger proportion of patients with symptoms only weakly
associated with colorectal cancer.
As the authors suggest, a set of variables may predict better
than individual symptoms and signs taken one at a time.
Table 1: Presenting symptoms and signs for 194 patients with 
colorectal cancer
Symptom Percentage of patients
Fecal occult blood test positive 77
Rectal bleeding 58
Anemia* 57
Abdominal pain 52
Weight loss 39
Anorexia 27
Constipation 27
Altered stools 25
Fatigue 25
Diarrhea 22
Nausea and vomiting 22
Tenesmus 8
Mucus in stools 6
Rectal pain 5
Obstruction 4
Adapted from Majumdar et al. [1].
*Anemia = a hemoglobin of < 13.4 g/dl in men or < 12.3 g/dl in 
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Predictive models for colorectal cancer have been devel-
oped [8-12]. Some of these models are designed to guide
primary prevention and include age and behavioral risk
factors such as smoking, diet, obesity, and exercise. Others
are for clinical cancer detection and include symptoms
and signs, as well as age. Models posted on the US
National Institutes of Health and Harvard Medical
School's public websites [11,12] take screening history
into account, as they should in settings such as the US
where colorectal cancer screening has been widely prac-
ticed for years. Unfortunately, no model so far, whether
for preventive care or clinical diagnosis, includes all of
these predictors. Even if one did, it might not produce
strong enough odds ratios to be as helpful in individual
patients as in groups of patients [13,14].
It is always difficult to choose a reasonable threshold for
further testing. Hamilton et al. assert that most would
agree that positive predictive values in the 2.4% to 4.5%
range, seen with rectal bleeding in men over 60 years, are
high enough to warrant investigation whereas positive
predictive values below 1.5% (as seen with constipation,
diarrhoea, abdominal pain, and loss of weight) reflect
'low-risk symptoms'. Other general practitioners in the
UK, or referral physicians, may have different opinions.
Care with high costs and low yield may be considered
worthwhile in one country but out of reach or profligate
in others. Also, the implementation of predictive models
are compromised to the extent that physicians feel
uncomfortable missing any cancers, no matter how low
the probability, and so make decisions using 'clinical
judgment' even when powerful predictive models exist
[15,16].
Will screening programs make the clinical diagnosis of
colorectal cancer a challenge of the past? Screening for
colorectal cancer has been shown to be effective and is
being implemented in many countries [17]. In the US,
nearly two-thirds of adults are being screened [18] and
colonoscopy is becoming the test of choice [19]. Other
countries have for the most part chosen fecal occult blood
testing for average risk adults [17]. Is it not likely that in
the future screening will find most cancers, or lead to their
prevention by removing polyps, so that the need for clin-
ical diagnosis will all but disappear. Probably not because
of the net effects of insensitive tests, refusal to be screened,
and new cancers in the interval between screenings. There-
fore, primary care physicians will remain at the front line
in the difficult task of distinguishing everyday symptoms
from life-threatening cancer.
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